共 101 条
[1]
Fruchart JC(2014)Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 13 26-1222
[2]
Davignon J(2017)Residual risk after treatment of patients with atherosclerotic cardiovascular disease with proprotein convertase subtilisin-kexin type 9 monoclonal antibody therapy (from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Trial) Am J Cardiol 120 1220-776
[3]
Hermans MP(2016)The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: the Jackson Heart Study Eur J Prev Cardiol. 23 769-24
[4]
Wong ND(2017)How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL Atherosclerosis Supplements 26 16-367
[5]
May HT(2014)Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment Pharmacol Ther 141 358-436
[6]
Nelson JR(2013)Remnant cholesterol as a causal risk factor for ischemic heart disease J Am Coll Cardiol 61 427-1309
[7]
Lirette ST(2013)Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation Circulation 128 1298-591
[8]
Averna Maurizio(2014)Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets Atherosclerosis. 235 585-219
[9]
Stroes Erik(2002)Remnant lipoproteins: measurement and clinical significance Clin Chem 48 217-781
[10]
Ogura Masatsune(2016)Remnant lipoprotein cholesterol and incident coronary heart disease: the Jackson Heart and Framingham Offspring Cohort Studies J Am Heart Assoc. 5 e002765-2192